参考文献：

1. Dickran Kazandjian, Gideon M Blumenthal, Huan-Yu Chen,et al.FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements[J]. Oncologist. 2014 Oct;19(10):e5-11.

2. Benjamin J Solomon, Tony Mok, Dong-Wan Kim, et al. Solomon BJ, et al. N Engl J Med. 2014 Dec 4;371(23):2167-77[J].N Engl J Med. 2014 Dec 4;371(23):2167-77.

3. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. J Thorac Oncol. 2021;16(12):2091-2108.

4. Brigatinib in Japanese patients (pts) with ALK+ NSCLC: Final results from the phase 2 J-ALTA trial. 2022 ASCO.Abstract #9075

5. R. Zheng, S. Zhang, H. Zeng et al.Cancer incidence and mortality in China, 2016[J].Journal of the National Cancer Center 2 (2022):1–9.

6. 张绪超,陆舜,张力等. 中国间变性淋巴瘤激酶(ALK)阳性非小细胞肺癌诊疗指南[J].中华病理学杂志,2015,44(10):696-703.

7.NCCN Guidelines.Non-Small Cell Lung Cancer.Version: 3.2022.

    以上就是本篇文章【钟文昭教授：一线治疗全面获益，ALK阳性肺癌新选择布格替尼强势来袭！】的全部内容了，欢迎阅览 ！ 文章地址：http://www.razcy.com/news/4824.html 
     资讯      企业新闻      行情      企业黄页      同类资讯      首页      网站地图      返回首页 月落星辰移动站 http://m.razcy.com/ , 查看更多